Phase I study of ruxolitinib in previously treated patients with low or intermediate-1 risk myelodysplastic syndrome with evidence of NF-kB activation

Yasmin Abaza,Juliana E. Hidalgo-Lopez,Srdan Verstovsek,Elias Jabbour,Farhad Ravandi,Gautam Borthakur,Zeev Estrov,Yesid Alvarado,Jan Burger,Heather Schneider,Kelly A. Soltysiak,Yue Wei,Hagop M. Kantarjian,Carlos E. Bueso-Ramos,Guillermo Garcia-Manero

Leukemia Research（2018）

引用 10|浏览15

暂无评分

摘要

•Deregulation of innate immune signaling is important in the pathogenesis of MDS.•Ruxolitinib is active in previously treated lower-risk MDS with NF-kB activation.•Reduction in pp65 expression may correlate with response duration.

查看译文

关键词

Myelodysplastic syndromes,NF-kB,Toll-like receptors,TNF-α,IL-8

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要